Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...

Merck says some patents for its top-selling cancer drug, Keytruda, may be extended through 2029.

Merck (MRK) ’s stock surged by 41% in the last six months, driven not only by a modest revenue increase but also by a ...

New KEYTRUDA indications are expected to preserve Merck's top line. Click here to read why MRK stock remains a great buy upon ...

Advocacy groups from 30 countries are urging Merck to create a global access strategy for its once-a-month HIV prevention ...

Hudson’s ousting follows a recent string of disappointing pipeline results for Sanofi.

Sanofi has replaced its CEO Paul Hudson after a series of R&D setbacks at the French pharma, handing the reins to Merck KGaA leader Belén Garijo.

But now, 13 years after the FDA initially blessed it for skin cancer, the U.S. regulator has approved Keytruda as a second- ...

Merck Foundation provided 1195 scholarships to women healthcare providers to empower women in science - International Day of Girls & Women in Science 2026 ...

Merck’s stock falls as the full-year revenue and profit outlooks were below expectations.

In what is shaping up to be a back-loaded month, the FDA is set to release a slew of regulatory decisions in February, ...

There will be a public meeting regarding the closure of the Cherokee Pharmaceuticals hazardous waste facility along the ...